FDA Withdraws Approval of Eight Generic Drug Applications
March 14, 2025
March 14, 2025
WASHINGTON, March 14 (TNSFR) -- The Food and Drug Administration (FDA) has announced the withdrawal of approval for eight abbreviated new drug applications (ANDAs) submitted by multiple pharmaceutical companies.
The affected drug products, which are no longer marketed, include treatments for bacterial infections, cardiovascular conditions, ophthalmic disorders, and allergies. The withdrawal follows formal requests from the applicants, who have waived their right to a hearing.
. . .
The affected drug products, which are no longer marketed, include treatments for bacterial infections, cardiovascular conditions, ophthalmic disorders, and allergies. The withdrawal follows formal requests from the applicants, who have waived their right to a hearing.
. . .